[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-hematologic-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-hematologic-neoplasm":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100553018","phase-2-effectiveness-and-safety-of-a-single-center-clinical-study-on-a-cd25-monoclonal-antibody-containing-gvhd-prophylaxis-scheme-to-reduce-the-incidence-of-severe-acute-gvhd-after-umbilical-cord-blood-transplantation-for-malignant-hematologic-diseases-100553018",false,"NCT06480630","Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases","Inclusion Criteria:\n\n* Malignant hematologic disorders;\n* Patients undergoing UCBT;\n* Female patients of childbearing potential must have a negative pregnancy test and agree to use effective contraception during treatment and for the following year.\n\nExclusion Criteria:\n\n* Non-malignant hematologic disorders;\n* History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation;\n* Uncontrolled bacterial, viral, or fungal infections. \"Uncontrolled\" is defined as lack of clinical improvement or progression despite adequate antimicrobial therapy;\n* HIV infection or active hepatitis B or C virus infection;\n* Pregnant or lactating women;\n* Substance abusers; subjects with uncontrolled psychiatric disorders; individuals with cognitive dysfunction;\n* Participation in similar clinical studies within the past 3 months;\n* Subjects deemed unsuitable by the investigator (e.g., those expected to be unable to adhere to treatment due to financial constraints).","ALL",{"count":17,"type":18},39,"ESTIMATED","INTERVENTIONAL",[21],"PHASE2","Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic disorders in reducing severe aGVHD.",[24,25],"Acute Graft Versus Host Disease","Malignant Hematologic Neoplasm","NOT_YET_RECRUITING","2024-06-25",{"date":29,"type":30},"2024-06-28","ACTUAL",{"date":32,"type":18},"2024-07-01",{"date":34,"type":18},"2027-06-30",{"name":36,"class":37},"Anhui Provincial Hospital","OTHER_GOV"]